Amgen Inc (AMGN)

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSJune 7, 2026 4:45 PM
PR Newswire (US) VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes CareTHOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and elevated LDL-C ("bad" cholesterol) without prior heart attack or stroke. Results from the analysis of 6,002 patients demonstrate that Repatha, when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction or ischemic stroke (3-P MACE) by 29% compared with placebo.Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization (4-P MACE) by 21%. The median achieved LDL-C was 45 mg/dL in the Repatha arm compared to 106 mg/dL with placebo (898 patients in the subgroup were part of a lipid sub-study).Approximately one-third and one-fifth of patients were on a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist, respectively, at some point during the study. Similar benefits were observed with Repatha regardless of whether patients were treated with these therapies, highlighting the importance of managing multiple risk factors in patients with high-risk diabetes, including treating uncontrolled LDL-C with Repatha."People with diabetes face double the risk of heart attack or stroke compared to those without the condition. These VESALIUS-CV results show that early, intensive LDL-C reduction to 45 mg/dL with Repatha is critical to help prevent life-altering cardiovascular events in those with high-risk disease," said Jay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data at Amgen. "Cardiometabolic conditions like elevated LDL-C and diabetes often coexist, compounding risk and leading to adverse outcomes. In addition to these data, Amgen is presenting real-world evidence that underscores the pressing need for continued long-term treatment to realize the full benefit of medical therapy for chronic conditions like diabetes, obesity and cardiovascular disease."Amgen presented multiple real-world evidence studies showing that while GLP-1 therapies can provide meaningful improvements in glycemic control and body weight, these benefits are closely tied to sustained treatment use. Across studies, persistence and adherence remained low in routine clinical practice, with many patients discontinuing treatment within the first year, potentially limiting the ability to achieve guideline-recommended HbA1c and weight goals and contributing to more modest outcomes than those seen in clinical trials. These findings highlight an important need for new treatment approaches and care strategies that may help patients stay on therapy longer and realize the full potential benefits of GLP-1 medicines.Key Amgen presentations during ADA 2026:Repatha (evolocumab) and LDL-CEvolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial
Abstract #1247-OR, Sunday, June 7 from 3:45 – 4:00 p.m. CDT
These data were simultaneously published in Diabetes Care.Lipid Management in Patients with High-Risk Diabetes Mellitus at Risk for a First Major Atherosclerotic Cardiovascular Event: Findings from the VESALIUS-REAL Global Study
Abstract #1448-P, Monday, June 8 from 12:30 – 1:30 p.m. CDTObesityReal-World HbA1c and Weight Change 6 and 12 Months by GLP-1 Treatment Persistence in Adults with Type 2 Diabetes
Abstract #1665-P, Presented Sunday, June 7Impact of GLP-1–Based Treatment Discontinuation on Weight Loss and Glycemic Goals Among Patients with Type 2 Diabetes: Quantifying an Opportunity to Improve Treatment Benefits
Abstract #1706-P, Presented Sunday, June 7A Meta-Analysis of Persistence and Adherence to Glucagon-Like Peptide-1-Based Treatments Among Patients with Type 2 Diabetes in the United States
Abstract #1691-P, Presented Sunday, June 7A Meta-Analysis of Real-World Effectiveness of Glucagon-Like Peptide-1s Among Patients with Type 2 Diabetes in the United States
Abstract #20-PUB, PublicationAbout the VESALIUS-CV Trial
VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled, global clinical trial designed to evaluate the impact of LDL-C lowering with evolocumab on MACE in adults at high CV risk without prior heart attack or stroke. Results were published in the New England Journal of Medicine in November 2025. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization (4-P MACE). Repatha also reduced the risk of heart attack by 36%.VESALIUS-CV enrolled more than 12,000 patients with known ASCVD or high-risk diabetes, who had no history of heart attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab testing. Participants were randomized to receive Repatha or placebo in addition to optimized lipid-lowering therapy and were followed for a median of approximately 4.6 years.Amgen's Commitment to Cardiometabolic Innovation
Amgen is redefining cardiometabolic care with cutting-edge science rooted in human biology that addresses closely connected cardiovascular and metabolic diseases that lead to serious outcomes or death.Cardiometabolic conditions commonly coexist and can lead to serious outcomes or death, even though they are treatable.1 Despite advances in lipid-lowering and metabolic therapies, substantial residual cardiovascular risk remains, driven by persistent LDL-C elevation, genetically mediated Lp(a) and obesity-related cardiometabolic dysfunction.2 Leveraging 40+ years of cutting-edge science and human genetics, Amgen is redefining cardiometabolic care and risk management. With years of success in cardiovascular disease with Repatha, Amgen is well positioned to deliver potential breakthrough medicines like MariTide and olpasiran to help address patient needs in cardiometabolic care and multiple interconnected drivers of cardiovascular and metabolic disease.About Repatha
Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.Repatha is one of the most extensively studied PCSK9 inhibitors, with clinical and real-world evidence across diverse populations and CV risk profiles.3 The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients.4 Repatha is the only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention, with patients achieving and maintain dramatic LDL-C reductions using Repatha only once every two weeks.5,6Repatha was first approved in 2015 and has since been used by more than 8 million patients globally.7,8 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to include adults at increased risk for major adverse CV events due to uncontrolled LDL-C. Repatha is approved in 74 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union.9 Applications in other countries are pending.INDICATIONS
 Repatha® is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor indicated:To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:adults with hypercholesterolemia.adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).The safety and effectiveness of Repatha® have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hypercholesterolemia. For full prescribing information, visit www.Repatha.com. IMPORTANT SAFETY INFORMATIONContraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.Adverse Reactions in Adults with Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo. Adverse Reactions in Pediatric Patients with HeFH: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.Adverse Reactions in Adults and Pediatric Patients with HoFH: In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.Please see full Prescribing Information. About Obesity
Obesity is a complex chronic disease influenced by genetic, behavioral and environmental factors, that increases the risk of many other serious related diseases and conditions, including type 2 diabetes, heart failure, sleep apnea, and cardiovascular disease.10,11 The worldwide prevalence of obesity more than doubled between 1990 and 2022.12 In the U.S., more than two in five adults (40.3%) are living with obesity.13 Globally, 1 billion people are living with obesity.14Obesity is linked to a marked reduction in quality of life and an array of serious medical complications and conditions.15,16 Though leading medical organizations, including the American Medical Association and the European Health Commission, recognize obesity as a chronic disease, only 1%-3% of eligible adults in the U.S. are prescribed medication for chronic weight management.17,18,19For more information about Amgen's approach to addressing obesity and related conditions, visit https://www.amgen.com/obesity.About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.CONTACT: Amgen, Thousand Oaks
Madison Howard, 773-636-4910 (media)
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors) REFERENCESEroglu T, Capone F, Schiattarella GG. The evolving landscape of cardiometabolic diseases. EBioMedicine. 2024 Nov;109:105447. doi: 10.1016/j.ebiom.2024.105447. Epub 2024 Nov 4. PMID: 39500010; PMCID: PMC11570325. Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol. 2026 Feb 26;18(2):114960. doi: 10.4330/wjc.v18.i2.114960. PMID: 41694036; PMCID: PMC12897005.Data on File; Amgen, 2025.Data on File; Amgen, 2025.Ndumele, C. E., & Blumenthal, R. S. (2025). VESALIUS and the Anatomy of High-Risk Prevention. New England Journal of Medicine. https://doi.org/10.1056/nejme2515447Marston, N. A., Bohula, E. A., Bhatia, A. K., et al. (2026). Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: Results from the VESALIUS-CV trial. JAMA. https://doi.org/10.1001/jama.2026.3277Shapiro MD. Circulation. 2022;146(15):1120-1122. Rao SV, O'Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862.Data on File. Amgen, 2025.Singh V, Sun J, Cheng S, Kwan AC, Velazquez A. Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization. Adv Ther. 2025;42(11):5341-5364.Health Risks of Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks. Published May 2023. Accessed April 27, 2026.World Health Organization. Obesity and overweight fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Updated March 1, 2024. Accessed May 14, 2026.Fryar CD, Afful J, Saif NT. Prevalence of overweight, obesity, and severe obesity among adults age 20 and over: United States, 1960–1962 through August 2021-August 2023. NCHS Health E-Stat. 2026 Feb;(111):1–7.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Mar 16;403(10431):1027-1050.Centers for Disease Control and Prevention. Consequences of Obesity. https://www.cdc.gov/obesity/basics/consequences.html. Accessed November 12, 2024.Hecker J, Freijer K, Hiligsmann M, Evers SMAA. Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. BMC Public Health. 2022;22:46.Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol. 2021;9(7):[418].American Medical Association House of Delegates, 2013. Recognition of obesity as a disease. Resolution 420 (A-13). May 16, 2013. Chicago, USA.Kim C, Ross JS, Jastreboff AM, et al. JAMA. 2025;333(24):2203–2206. View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-diabetes-association-86th-scientific-sessions-302793408.htmlSOURCE Amgen Original: AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCEMay 29, 2026 4:01 PM
PR Newswire (US) THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, Narimon Honarpour, senior vice president of global development at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media) 
Casey Capparelli, 805-447-1746 (investors)  View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-jefferies-global-healthcare-conference-302785887.htmlSOURCE Amgen Original: AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITHMay 19, 2026 4:05 PM
PR Newswire (US) Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020. The company also announced that Thomas Dittrich will return to Amgen as executive vice president on July 1 and succeed Griffith as chief financial officer effective September 1, 2026."We are grateful to Peter for his leadership and lasting impact on the company," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Peter has helped position Amgen to deliver attractive long-term growth and expand our ability to serve patients in the years ahead."During his tenure, Griffith strengthened the company's financial foundation, supported disciplined capital allocation and helped advance Amgen's long-term growth strategy across the business.Dittrich, who previously held senior finance roles at Amgen, brings more than 30 years of international leadership experience to the company, along with a strong understanding of the biopharmaceutical industry and consumer-focused healthcare markets. Most recently, he served as chief financial officer of Galderma. Prior to that, he served as chief financial officer at both Shire and Sulzer. Dittrich will oversee all aspects of Amgen's financial operations. Griffith will remain with the company into January 2027 to support a seamless transition.About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads. Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.CONTACT: Amgen, Thousand Oaks?
Elissa Snook, 609-251-1407 (media)
Alison Chartan, 301-742-9584 (media)
Casey Capparelli, 805-447-1746 (investors)? View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-retirement-of-chief-financial-officer-peter-griffith-302776750.htmlSOURCE Amgen Original: AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchMay 13, 2026 9:00 AM
InvestorsHub NewsWireCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchBioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier ("BBB"), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous system ("CNS"). Oncotelic has developed a proprietary intranasal nose-to-brain ("N2B") system capable of rapidly shuttling therapeutics to the brain, a signal of growing industry consensus that delivery innovation, not merely drug discovery, will drive the next wave of breakthroughs in CNS medicine. Oncotelic joins a group of leading biopharma companies working in the biopharmaceutical and advanced therapeutics space, including Amgen Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) and Lunai Bioworks Inc. (NASDAQ: LNAI).While the blood-brain barrier is vital for maintaining neurological health, it simultaneously creates a major obstacle for drug developers.Oncotelic Therapeutics is pursuing a position in a segment of the market focused on enabling faster, more reliable access to the brain.CNS drug delivery is not only a concern for chronic disease, it is also a strategic priority in the area of national security and biodefense.Designed as a device-enabled approach to direct CNS delivery, Oncotelic's N2B delivery system offers a potential alternative to traditional systemic or intramuscular routes.Oncotelic Therapeutics is building along these lines. Its focus on scalable, adaptable delivery infrastructure positions the company to pursue multiple CNS indications from a shared platform base.Click here to view the custom infographic of the Oncotelic Therapeutics editorial.Why the Blood-Brain Barrier Is So Difficult to OvercomeThe blood-brain barrier functions as a tightly regulated biological filter, shielding brain tissue from harmful substances traveling through the bloodstream. While this defense mechanism is vital for maintaining neurological health, it simultaneously creates a major obstacle for drug developers. Research shows that the BBB blocks the passage of most chemical compounds, permitting entry only to certain molecules that meet narrow size and chemistry criteria. The result is that even promising therapeutic candidates often fail to produce meaningful effects simply because they cannot reach the brain in sufficient concentrations.The scale of this problem is striking. Scientific consensus suggests that close to 98% of small-molecule drugs and virtually all biologic therapies are unable to cross the BBB effectively, making this a defining limitation in CNS pharmaceutical development. It also contributes disproportionately to clinical trial failures in neurology, compounds that show real therapeutic promise may nonetheless stumble in trials not because the drug is ineffective, but because it cannot reach its target.The downstream consequences reach across some of the most prevalent and devastating conditions in neurology, from Alzheimer's and Parkinson's disease to primary brain tumors. After decades of intensive research and massive capital investment, effective treatment options for many CNS disorders remain frustratingly scarce. The persistent failure to achieve adequate drug concentrations in the brain has slowed progress across the field, making the search for workable delivery solutions an urgent scientific and commercial priority.Within this context, Oncotelic Therapeutics is developing technologies specifically aimed at getting around these BBB limitations. A concrete marker of progress is the company's recent announcement that it has finalized a strategic monetization agreement with Lunai Bioworks, in which Oncotelic transferred rights to its N2B delivery system for defined applications in biodefense and Alzheimer's disease."Under the terms of the agreement, Oncotelic has granted Lunai Bioworks worldwide rights to the N2B delivery system IP portfolio within defined fields, specifically biodefense medical countermeasures and Alzheimer's disease only," the announcement stated. "The company continues to evaluate additional partnerships to further monetize its portfolio while maintaining strategic control over core assets."By treating delivery infrastructure as a core asset rather than a secondary consideration, Oncotelic is positioning itself within a broader industry move toward integrated solutions that attack the CNS delivery problem head-on.The Growing Weight of Alzheimer's, Neurological DiseaseThe worldwide toll of Alzheimer's disease and other similar forms of dementia is expanding at an alarming pace. According to the World Health Organization, some 57 million people are currently living with dementia globally, a figure projected to grow sharply in the decades ahead as aging populations increase. The human and economic costs of this expansion are substantial, placing mounting pressure on healthcare systems, families, and public finances.Despite this, therapeutic progress has moved slowly. The Alzheimer's Association notes that while researchers have made meaningful strides in understanding the disease at a molecular level, clinical translation has lagged. Drug candidates that look compelling in preclinical settings frequently falter in human trials, often because adequate therapeutic concentrations cannot be sustained within brain tissue, a problem that loops directly back to delivery.New developments across the biopharma landscape highlight both the promise and the stubborn limitations of current approaches. Therapies with demonstrated clinical signals still face ongoing scrutiny over whether effects are consistent and durable, and debates frequently return to the challenge of achieving reliable drug exposure in the brain. These dynamics  support the view that delivery remains one of the defining bottlenecks in CNS medicine.Against this backdrop, Oncotelic Therapeutics is pursuing a position in a segment of the market focused on enabling faster, more reliable access to the brain. By orienting its platform toward targeted and precision delivery, the company is placing itself within a space where solving the delivery problem could substantially improve results across a spectrum of neurodegenerative conditions.Biodefense and the Imperative for Fast CNS InterventionCNS drug delivery is not only a concern for chronic disease, it is also a strategic priority in the area of national security and biodefense. Certain chemical and biological threats act directly on the nervous system, and when they do, the window for effective intervention can be extremely narrow. In these high-stakes scenarios, how fast and how effectively a treatment reaches the brain can mean the difference between survival and catastrophic neurological damage.Federal agencies have taken notice. The Biomedical Advanced Research and Development Authority ("BARDA") plays a leading role in funding medical countermeasure development for chemical, biological, radiological, and nuclear threats. Meanwhile, the U.S. Department of Defense has identified CNS injury treatment and neuroprotection as core research areas, a reflection of the operational importance of maintaining neurological function in personnel exposed to hazardous environments.These policy priorities converge on a shared need: Delivery systems that work fast, bypass conventional physiological obstacles, and ensure therapeutics arrive in the brain at concentrations sufficient to produce meaningful effects. When minutes matter, inefficient delivery translates directly into worsened outcomes.Oncotelic Therapeutics is navigating this landscape by exploring applications of its delivery technology that span both commercial medicine and government-funded biodefense programs. This dual-use potential, which is capable of addressing both civilian neurological diseases and emergency response needs, reflects a broader movement toward versatile platforms that can generate value across multiple high-impact markets.Nose-to-Brain Delivery Emerges as a Leading AlternativeWith conventional drug delivery approaches repeatedly running into BBB-related constraints, alternative methods that circumvent the barrier entirely are attracting growing scientific and commercial interest. Among them, intranasal, or "nose-to-brain," delivery has established itself as a particularly compelling option. This pathway leverages anatomical connections between the nasal passages and the brain to transport therapeutic agents directly into CNS tissue, bypassing the bloodstream altogether.Research highlights the capacity of intranasal delivery systems to meaningfully improve drug transport to the brain while keeping systemic exposure low. Evidence from multiple studies indicates that this approach can raise bioavailability and reduce adverse effects—a combination that makes it attractive for long-term use in neurological conditions where patients require sustained treatment.Industry analysis from Deloitte reinforces this trend, noting that CNS therapeutic innovation is shifting its center of gravity from new molecular entities toward delivery technologies. As pharmaceutical and biotech companies seek more consistent clinical outcomes, the ability to get drugs to the right place in the right amounts is increasingly the variable that separates success from failure.Oncotelic's N2B delivery system embodies this philosophy. Designed as a device-enabled approach to direct CNS delivery, it offers a potential alternative to traditional systemic or intramuscular routes. By bypassing the blood-brain barrier, the platform is engineered to accelerate therapeutic onset and improve targeting of the neurological pathways implicated in both acute biodefense emergencies and chronic conditions like Alzheimer's disease.Platform Strategies Are Reshaping CNS InnovationThe trajectory of CNS drug development is moving away from single-asset bets and toward platform-based architectures that can support multiple therapies, indications and commercial pathways. Unlike conventional drug development models, platform approaches offer scalability and adaptability, both qualities particularly suited to an area such as CNS medicine, where diverse conditions often share the same core delivery challenges.Platform-based models allow companies to spread risk across multiple programs while building on a shared technological foundation. By engineering systems that can be configured for different drugs or conditions, developers create multiple routes to revenue while reducing overexposure to any single program's outcome. This structure also aligns naturally with the principles of precision medicine, in which targeted delivery is integral to achieving outcomes that are both effective and patient-specific.For investors, platform strategies carry a distinct appeal. They offer exposure across a range of markets, including neurodegenerative diseases and biodefense, while creating natural opportunities for partnerships, out-licensing, and monetization. This blend of near-term revenue potential with long-term pipeline value is especially compelling in a sector where timelines are long and the risk of any individual asset failing is high.Oncotelic Therapeutics is building along these lines. Its focus on scalable, adaptable delivery infrastructure positions the company to pursue multiple CNS indications from a shared platform base. By combining short-term monetization strategies, such as the Lunai Bioworks agreement, with longer-term development opportunities, the company reflects an industry-wide shift toward approaches that address both the scientific complexity and the commercial realities of the CNS space.The challenge of delivering drugs to the brain persists as one of the most consequential barriers in contemporary medicine. With Alzheimer's disease caseloads climbing and national attention focusing on biodefense, the demand for faster and more reliable CNS delivery solutions is intensifying. Meeting that demand will require progress not just in discovering new compounds but in reimagining how those compounds are transported to their targets.Companies working to overcome the blood-brain barrier and enable targeted, efficient brain delivery are staking out positions at the leading edge of a significant shift. Oncotelic Therapeutics is one participant in this broader movement, advancing platform-based approaches designed to expand what is therapeutically possible in CNS medicine. As the field continues to evolve, the capacity to deliver drugs reliably and precisely to the brain may well emerge as the central determinant of future medical progress.Biopharma Innovation Continues Advancing TherapeuticsThe biopharma and advanced therapeutics sector continues to see strong momentum as companies expand research pipelines, pursue strategic partnerships and accelerate development of next-generation treatments targeting complex diseases. Recent announcements across oncology, immunology and precision medicine highlight growing investment in innovative biologics, AI-driven drug discovery, targeted therapies and advanced platform technologies designed to improve outcomes for patients with difficult-to-treat conditions.Amgen Inc. (NASDAQ: AMGN) has acquired Dark Blue Therapeutics, a move that will bolster the company's oncology pipeline and expand its capabilities in targeted protein degradation and leukemia therapeutics. The company noted that acute myeloid leukemia remains one of the most difficult cancers to treat and that the acquisition complements and extends its research in targeted protein degradation and leukemia therapeutics, as well as advances its strategy to invest in novel therapeutic targets and next-generation oncology medicines designed to address difficult-to-treat cancers.Johnson & Johnson (NYSE: JNJ) continues advancing its position in the biopharma and advanced therapeutics space through its Innovative Medicine division, which the company describes as "leading where medicine is going." According to JNJ, patients inform and inspire the company's science-based innovations, which continue to change and save lives with rigorous science and compassion by addressing the most complex diseases and focusing on unlock the medicines of tomorrow. The company's areas of healthcare focus include oncology, immunology, neuroscience and cardiopulmonary.AbbVie Inc. (NYSE: ABBV) has entered an exclusive licensing agreement with RemeGen for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ("PD-1")/Vascular Endothelial Growth Factor ("VEGF")-targeted bispecific antibody. RC148 is being developed both as a monotherapy and in combination regimens across multiple advanced solid tumors, reinforcing the company's continued expansion in next-generation oncology therapeutics. The agreement reflects AbbVie's strategy to strengthen its oncology pipeline through innovative biologics and advanced immunotherapy approaches targeting difficult cancers.Lunai Bioworks Inc. (NASDAQ: LNAI) announced the launch of an AI oncology pilot with a clinical-stage partner to analyze randomized phase 2 metastatic colorectal cancer survival trial data. The objective of the partnership is to define biologically meaningful patient subgroups that may benefit most from the investigational therapy. Under the pilot agreement, Lunai will deploy its proprietary Augusta AI platform to evaluate de-identified patient-level clinical, imaging, and longitudinal outcomes data, with a focus on overall survival and disease progression endpoints. By integrating traditional clinical variables with AI-derived imaging features and temporal response patterns, Lunai aims to generate data-driven enrichment strategies designed aid in the FDA trial design, including optimized inclusion criteria, endpoint strategy, and its statistical powering.These developments reflect the increasing importance of scientific innovation, data-driven discovery and advanced therapeutic modalities in shaping the future of medicine. As the industry continues evolving toward more personalized, targeted and technology-enabled approaches, companies operating in the space are positioning themselves to play a major role in advancing treatment options across a broad range of serious diseases.For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.About BioMedWireBioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, "Biotech" to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.comBioMedWire is powered by IBN Original: CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research

AMGN, shorts in control

/C O R R E C T I O N -- Amgen/April 30, 2026 7:02 PM
PR Newswire (US)

In the news release, AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS, issued 30-Apr-2026 by Amgen over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026."Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected patent expirations and increased competition. With a new wave of molecules progressing in Phase 3 clinical development, we're confident in our ability to deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer.Key results include:For the first quarter, total revenues increased 6% to $8.6 billion in comparison to the first quarter of 2025.Product sales grew 4%, driven by 9% volume growth, partially offset by 2% lower net selling price and 2% from lower inventory levels.Sixteen products delivered at least double-digit sales growth in the first quarter.Seventeen products annualizing at more than $1 billion based on first quarter sales.GAAP earnings per share (EPS) increased 4% from $3.20 to $3.34 for the first quarter, driven by higher operating income, partially offset by net unrealized losses on equity investments in the current-year period compared to net unrealized gains in the prior-year period.For the first quarter, GAAP operating income increased from $1.2 billion to $2.7 billion, and GAAP operating margin increased 17.4 percentage points to 32.4%.Non-GAAP EPS increased 5% from $4.90 to $5.15 for the first quarter, driven by higher revenues, partially offset by higher operating expenses.For the first quarter, non-GAAP operating income increased from $3.6 billion to $3.7 billion, and non-GAAP operating margin decreased 0.4 percentage points to 45.3%.The Company generated $1.5 billion of free cash flow for the first quarter of 2026 versus $1.0 billion for the first quarter of 2025, driven by business performance and timing of working capital, partially offset by higher capital expenditures.References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.Product Sales PerformanceGeneral MedicineRepatha® (evolocumab) sales increased 34% year-over-year to $876 million in the first quarter, driven by 35% volume growth and 8% favorable changes to estimated sales deductions, partially offset by 7% lower net selling price.EVENITY® (romosozumab-aqqg) sales increased 27% year-over-year to $562 million in the first quarter, driven by volume growth.Prolia® (denosumab) sales decreased 34% year-over-year to $727 million in the first quarter, primarily driven by 17% lower volume, 10% lower net selling price, and 4% from lower inventory levels. For 2026, we continue to expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched globally.Rare DiseaseTEPEZZA® (teprotumumab-trbw) sales increased 29% year-over-year to $490 million in the first quarter, driven by a 22% impact from higher inventory levels and higher net selling price.KRYSTEXXA® (pegloticase) sales increased 8% year-over-year to $255 million in the first quarter, primarily driven by 20% higher net selling price, partially offset by 8% from lower inventory levels and unfavorable changes to estimated sales deductions.UPLIZNA® (inebilizumab-cdon) sales increased 188% year-over-year to $262 million in the first quarter, primarily driven by volume growth.TAVNEOS® (avacopan) sales increased 32% year-over-year to $119 million in the first quarter, driven by 55% volume growth, partially offset by 15% from lower inventory levels.InflammationTEZSPIRE® (tezepelumab-ekko) sales increased 20% year-over-year to $343 million in the first quarter, driven by 32% volume growth, partially offset by 8% from lower inventory levels.Otezla® (apremilast) sales decreased 1% year-over-year to $431 million in the first quarter, as 8% lower net selling price and 2% lower volume were offset by favorable changes to estimated sales deductions.Enbrel® (etanercept) sales decreased 37% year-over-year to $320 million in the first quarter, primarily driven by unfavorable changes to estimated sales deductions of 18% and 15% lower net selling price. The decline in net selling price reflects the impact of U.S. Medicare Part D price setting under the Inflation Reduction Act, effective January 1, 2026, as well as an increased 340B Program mix.AMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab) sales increased 27% year-over-year to $173 million in the first quarter, primarily driven by 18% higher net selling price and 8% favorable foreign exchange impact.PAVBLU® (aflibercept-ayyh) generated $280 million in the first quarter. Sales increased 9% quarter-over-quarter, driven by 16% volume growth, partially offset by 9% from lower inventory levels.OncologyBLINCYTO® (blinatumomab) sales increased 12% year-over-year to $415 million in the first quarter, driven by 19% volume growth, partially offset by unfavorable changes to estimated sales deductions.IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) sales increased 219% year-over-year to $258 million in the first quarter, driven by volume growth.
Vectibix® (panitumumab) sales increased 7% year-over-year to $287 million in the first quarter, driven by 11% volume growth, partially offset by lower inventory levels. KYPROLIS® (carfilzomib) sales increased 2% year-over-year to $330 million in the first quarter, primarily driven by higher net selling price.LUMAKRAS®/LUMYKRAS™ (sotorasib) sales increased 11% year-over-year to $94 million in the first quarter, driven by volume growth.Nplate® (romiplostim) sales increased 32% year-over-year to $412 million in the first quarter. Excluding the U.S. government order of $60 million in the first quarter of 2026, Nplate sales increased 12%, driven by 8% volume growth and higher net selling price.XGEVA® (denosumab) sales decreased 27% year-over-year to $411 million in the first quarter, driven by 19% lower volume and lower net selling price. For 2026, we continue to expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched globally.MVASI® (bevacizumab-awwb) sales decreased 16% year-over-year to $150 million in the first quarter, driven by 8% lower net selling price and 7% unfavorable changes to estimated sales deductions.Established ProductsOur established products, which consist of Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim) and Parsabiv® (etelcalcetide), generated $563 million of sales in the first quarter. Sales increased 1% year-over-year, driven by 10% higher net selling price, partially offset by 4% lower volume and 4% unfavorable changes to estimated sales deductions.Product Sales Detail by Product and Geographic Region$Millions, except percentages
Q1 '26
Q1 '25
YOY ?

U.S
ROW
TOTAL
TOTAL
TOTALRepatha®
$       465
$       411
$        876
$       656
34 %EVENITY®
431
131
562
442
27 %Prolia®
461
266
727
1,099
(34 %)TEPEZZA®
424
66
490
381
29 %KRYSTEXXA®
255
—
255
236
8 %UPLIZNA®
246
16
262
91
*TAVNEOS®
114
5
119
90
32 %Ultra-Rare products(1)
96
2
98
179
(45 %)TEZSPIRE®
343
—
343
285
20 %Otezla®
352
79
431
437
(1 %)Enbrel®
314
6
320
510
(37 %)AMJEVITA®/AMGEVITA™
41
132
173
136
27 %PAVBLU®
276
4
280
99
*WEZLANA®/WEZENLA™
4
43
47
150
(69 %)BLINCYTO®
221
194
415
370
12 %IMDELLTRA®/IMDYLLTRA™
188
70
258
81
*Vectibix®
136
151
287
267
7 %KYPROLIS®
218
112
330
324
2 %LUMAKRAS®/LUMYKRAS™
49
45
94
85
11 %Nplate®
283
129
412
313
32 %XGEVA®
228
183
411
566
(27 %)MVASI®
96
54
150
179
(16 %)Aranesp®
77
234
311
340
(9 %)Neulasta®
149
16
165
129
28 %Parsabiv®
43
44
87
88
(1 %)Other products(2)
263
52
315
340
(7 %)Total product sales
$     5,773
$     2,445
$     8,218
$     7,873
4 %










* Change in excess of 100%









(1) Ultra-Rare products consist of PROCYSBI®, RAVICTI®, ACTIMMUNE®, BUPHENYL® and QUINSAIR®.(2) Other products consist of Aimovig®, KANJINTI®, AVSOLA®, BKEMV®/BEKEMV™, RIABNI®, EPOGEN®, NEUPOGEN®, IMLYGIC®, Sensipar®/Mimpara™, RAYOS®, DUEXIS®, Corlanor®, and PENNSAID®. Biosimilars total $185 million in Q1 '26 and $171 million in Q1 '25. Rare Disease total ($3) million in Q1 '26 and ($1) million in Q1 '25.Operating Expense, Operating Margin and Tax Rate AnalysisOn a GAAP basis:Total Operating Expenses decreased 15% year-over-year for the first quarter. Cost of Sales as a percentage of product sales decreased 4.3 percentage points, driven by lower amortization expense from acquisition-related assets, partially offset by higher profit share and royalty expense and changes in our sales mix. Research & Development (R&D) expenses increased 16% driven by higher spend in Later-Stage Clinical Programs, including those related to MariTide. Selling, General & Administrative (SG&A) expenses decreased 5% driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses. Other operating income for the first quarter included litigation settlements.Operating Margin as a percentage of product sales increased 17.4 percentage points to 32.4%.Tax Rate increased 0.4 percentage points for the first quarter primarily driven by the change in earnings mix, including lower amortization expense from acquisition-related assets, partially offset by the net unrealized losses on our equity investments in the current-year period compared to net unrealized gains in the prior-year period.On a non-GAAP basis:Total Operating Expenses increased 8% year-over-year for the first quarter. Cost of Sales as a percentage of product sales increased 1.5 percentage points, driven by higher profit share and royalty expense and changes in our sales mix. R&D expenses increased 16% driven by higher spend in Later-Stage Clinical Programs, including those related to MariTide. SG&A expenses decreased 4% driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses. Operating Margin as a percentage of product sales decreased 0.4 percentage points for the first quarter to 45.3%. Tax Rate decreased 1.0 percentage points for the first quarter primarily driven by net favorable items in the current-year period, partially offset by the change in earnings mix.$Millions, except percentages
GAAP
Non-GAAP

Q1 '26
Q1 '25
YOY ?
Q1 '26
Q1 '25
YOY ?Cost of Sales
$  2,744
$  2,968
(8 %)
$  1,603
$  1,420
13 %% of product sales
33.4 %
37.7 %
(4.3) pts
19.5 %
18.0 %
1.5 ptsResearch & Development
$  1,719
$  1,486
16 %
$  1,711
$  1,475
16 %% of product sales
20.9 %
18.9 %
2.0 pts
20.8 %
18.7 %
2.1 ptsSelling, General & Administrative
$  1,602
$  1,687
(5 %)
$  1,583
$  1,655
(4 %)% of product sales
19.5 %
21.4 %
(1.9) pts
19.3 %
21.0 %
(1.7) ptsOther
$   (113)
$     830
*
$       —
$       —
N/ATotal Operating Expenses
$  5,952
$  6,971
(15 %)
$  4,897
$  4,550
8 %












Operating Margin











Operating income as % of product sales
32.4 %
15.0 %
17.4 pts
45.3 %
45.7 %
(0.4) pts












Tax Rate
12.7 %
12.3 %
0.4 pts
13.6 %
14.6 %
(1.0) pts












pts: percentage points











* = Change in excess of 100%











N/A = not applicable











Cash Flow and Balance SheetThe Company generated $1.5 billion of free cash flow in the first quarter of 2026 versus $1.0 billion in the first quarter of 2025, driven by business performance and timing of working capital, partially offset by higher capital expenditures.The Company declared a first quarter 2026 dividend on December 9, 2025 of $2.52 per share that was paid on March 6, 2026 to all stockholders of record as of February 13, 2026, representing a 6% increase from the same period in 2025.During the first quarter of 2026, there were no repurchases of shares of common stock under our stock repurchase program.Cash and cash equivalents totaled $12.0 billion and debt outstanding totaled $57.3 billion as of March 31, 2026.$Billions, except shares
Q1 '26
Q1 '25
YOY ?Operating Cash Flow
$        2.2
$        1.4
$        0.8Capital Expenditures
$        0.7
$        0.4
$        0.3Free Cash Flow
$        1.5
$        1.0
$        0.5Dividends Paid
$        1.4
$        1.3
$        0.1Share Repurchases
$        0.0
$        0.0
$        0.0Average Diluted Shares (millions)
544
541
3






Note: Numbers may not add due to rounding




$Billions
3/31/26
12/31/25
YTD ?Cash and Cash Equivalents
$      12.0
$        9.1
$        2.9Debt Outstanding
$      57.3
$      54.6
$        2.7






Note: Numbers may not add due to rounding



2026 GuidanceFor the full year 2026, the Company expects:Total revenues in the range of $37.1 billion to $38.5 billion.On a GAAP basis, EPS in the range of $15.62 to $17.10, and a tax rate in the range of 14.5% to 16.0%.On a non-GAAP basis, EPS in the range of $21.70 to $23.10, and a tax rate in the range of 15.0% to 16.5%.Capital expenditures to be approximately $2.6 billion.Share repurchases not to exceed $3.0 billion.First Quarter Product and Pipeline UpdateThe Company provided the following updates on selected product and pipeline programs:General MedicineMariTide (maridebart cafraglutide, AMG 133)MariTide is a differentiated antibody-peptide conjugate that activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR) featuring monthly or less frequent dosing.MARITIME-1, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D).MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D.MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, is enrolling adults living with established atherosclerotic cardiovascular disease and obesity or overweight.MARITIME-HF, a Phase 3 study of MariTide on reduction of heart failure events and cardiovascular risk, is enrolling adults living with heart failure with preserved or mildly reduced ejection fraction and obesity.MARITIME-OSA-1, a Phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea on positive airway pressure therapy and living with obesity or overweight.MARITIME-OSA-2, a Phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea not on positive airway pressure therapy and living with obesity or overweight.MARITIME-SWITCH, a Phase 3 study of MariTide, was initiated in adults living with obesity or overweight who will be switching from weekly tirzepatide or weekly semaglutide to MariTide on an every eight-week or quarterly dosing schedule.MARITIME-1 EXTENSION, a Phase 3 long-term extension study of MariTide, was initiated to evaluate the maintenance of weight loss with monthly, every eight-week or quarterly dosing in adults living with obesity or overweight without T2D who completed the MARITIME-1 study.MARITIME-2 EXTENSION, a Phase 3 long-term extension study of MariTide, was initiated to evaluate the maintenance of weight loss with monthly and every eight-week dosing in adults living with obesity or overweight with T2D who completed the MARITIME-2 study.Three Phase 3 studies of MariTide in people living with T2D will be initiated in 2026.A Phase 2b study of MariTide to assess the effect of MariTide on liver fat reduction and weight loss was initiated and is enrolling adults living with obesity or overweight with elevated liver fat.AMG 513A Phase 1 study of AMG 513 is enrolling adults living with obesity.RepathaIn March, results from a new subgroup analysis of the Phase 3 VESALIUS-CV clinical trial were presented at the American College of Cardiology Annual Scientific Session and simultaneously published in the Journal of the American Medical Association. In this subset of 3,655 high-risk patients with diabetes without known significant atherosclerosis, Repatha:demonstrated a 31% relative reduction in the risk of a composite of coronary heart disease death, heart attack or ischemic stroke (3-P MACE).demonstrated a 31% reduction in a broader composite that also included ischemia-driven revascularization (4-P MACE).reduced the risk of heart attack also by 31%.was associated with a nominal 32% decreased risk of cardiovascular death and a 24% decreased risk of all-cause death.Further subgroup analysis from VESALIUS-CV in patients who had a prior percutaneous coronary intervention will be presented at the upcoming European Course on Percutaneous Cardiovascular Interventions in May.Further subgroup analysis from VESALIUS-CV in patients with high-risk of diabetes with and without known atherosclerosis will be presented at the upcoming American Diabetes Association Scientific Sessions in June.EVOLVE-MI, a Phase 4 study of Repatha initiated within 10 days of an acute myocardial infarction to reduce the risk of cardiovascular events, is ongoing.Olpasiran (AMG 890)Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver.The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV disease and elevated Lp(a).The OCEAN(a)-PreEvent trial, a Phase 3 primary prevention CV outcomes study, is enrolling patients with elevated Lp(a) at high risk for a first major CV event.The OCEAN(a)-Coronary Computed Tomography Angiography (CCTA), a Phase 3 coronary artery plaque study, was initiated and is enrolling patients with atherosclerotic CV disease and elevated Lp(a).Rare DiseaseUPLIZNAIn February, the European Commission approved UPLIZNA as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.Phase 3 studies of UPLIZNA in patients with autoimmune hepatitis and in patients with chronic inflammatory demyelinating polyneuropathy will be initiated H2 2026.TEPEZZAIn April, the Company announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector (OBI) in adults with moderate-to-severe active Thyroid Eye Disease (TED). In this study, TEPEZZA OBI:showed comparable efficacy to intravenous (IV) TEPEZZA.achieved the primary endpoint with a 77% proptosis response rate at week 24 compared to 19.6% for placebo (p

AMGN! Trending sideways

AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTSApril 24, 2026 4:01 PM
PR Newswire (US)

THOUSAND OAKS, Calif., April 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors) 





View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-webcast-of-2026-first-quarter-financial-results-302753310.htmlSOURCE Amgen

Original: AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS

AMGN, nice rally

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASEApril 6, 2026 9:00 AM
PR Newswire (US)

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mmTHOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED). TEPEZZA OBI provides comparable efficacy to, and builds upon the success of, intravenous (IV) TEPEZZA, the first and only medicine approved for the treatment of TED, which has now treated more than 25,000 patients worldwide.The Phase 3 TEPEZZA OBI trial met its primary endpoint in moderate-to-severe active TED, showing a statistically significant and clinically meaningful 77% proptosis response rate during the 24-week placebo-controlled period (76.7% TEPEZZA OBI vs. 19.6% placebo [p

AMGN, trending sideways

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSISMarch 28, 2026 4:45 PM
PR Newswire (US)

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary PreventionVESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C AchievedTHOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes. The findings were presented in a late-breaking session at the American College of Cardiology (ACC) 75th Annual Scientific Session and simultaneously published in the Journal of the American Medical Association.The results are from a new subgroup analysis of 3,655 patients at increased risk of CV events without known significant atherosclerosis (all of whom had diabetes) followed for a median of 4.8 years from the Phase 3 VESALIUS-CV clinical trial. Results showed Repatha reduced the risk of the composite primary endpoint of coronary heart disease (CHD) death, myocardial infarction or ischemic stroke (3-P MACE) by 31% compared with placebo. Repatha also reduced the risk of a dual composite primary endpoint that included ischemia-driven revascularization (4-P MACE) by 31%. The median achieved LDL-C was 44 mg/dL at 96 weeks in the Repatha added to optimized lipid-lowering therapy arm compared to 105 mg/dL in the placebo plus optimized lipid-lowering therapy arm (548 patients in the subgroup were part of a lipid sub-study)."The evidence is unequivocal: Intensive LDL-C lowering with Repatha significantly reduces the risk of major CV events for high-risk patients," said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. "The new ACC/AHA Multisociety Guideline on the Management of Dyslipidemia reinforces the importance of earlier, more intensive lowering of LDL-C to prevent CV events. VESALIUS-CV builds on this, showing that in high-risk patients without prior heart attack or stroke, lowering LDL-C beyond what is typically achieved today can meaningfully reduce risk before ASCVD takes hold. These data also show the benefit of lowering LDL-C below 45 mg/dL with Repatha, a level that may not be achieved with statins or ezetimibe alone. Now is the time to treat earlier and help all appropriate patients reach lower LDL-C goals."Across secondary endpoints, Repatha demonstrated consistent benefit, including the following composite endpoints: heart attack, ischemic stroke or any ischemia-driven revascularization; CHD death, heart attack or revascularization; CV death, heart attack or ischemic stroke. Among individual secondary endpoints, Repatha showed numerical reductions in the risk of heart attack by 31%, ischemia-driven revascularization by 34% and ischemic stroke by 33%. Repatha demonstrated numerical trends for reduced mortality rates, including CV death (32% relative risk reduction), CHD death (27% relative risk reduction) and all-cause death (24% relative risk reduction)."This analysis clearly demonstrates that the CV benefit of evolocumab in the VESALIUS-CV study includes those who had no known ASCVD, or significant plaque buildup in the arteries," said Nicholas Marston, M.D., M.P.H., assistant professor of medicine, member of the TIMI Study Group and cardiologist at Brigham and Women's Hospital and Harvard Medical School. "Lowering LDL-C earlier with more intensive therapy in high-risk primary prevention patients, before plaque becomes advanced, can prevent the clinical onset of heart disease. These findings confirm the substantial risk reduction that can be achieved by treating more proactively with evolocumab rather than waiting for the development of significant atherosclerosis or a CV event to then intensify lipid-lowering therapy."For more information on Amgen abstracts and presentation times at the ACC 75th Annual Scientific Session, see below.Evolocumab for the Reduction of First Major Cardiovascular Events in Patients without Significant Atherosclerosis: Results from VESALIUS-CV
LBS.105, Saturday, March 28 from 4:00 - 4:10 p.m. CSTLDL-C Lowering and Associated Risk Reduction of Myocardial Infarction and Stroke-Related Hospitalizations in Patients with ASCVD and Diabetes
Abstract #1165-11, Monday, March 30 from 10:18 - 10:25 a.m. CSTCardiovascular disease (CVD) is the leading cause of death worldwide, and most CV events occur in people without a prior history of heart attack or stroke.1 High LDL-C is one of the most modifiable risk factors for heart attack and stroke, and prolonged exposure to elevated LDL-C increases CV risk over time, making earlier and more intensive LDL-C lowering critical to reducing the risk of a first CV event.2,3,4Repatha was first approved in 2015 and has since been used by more than 8 million patients globally.5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to include adults at increased risk for major adverse CV events due to uncontrolled LDL-C.About the VESALIUS-CV Trial
VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled, global clinical trial designed to evaluate the impact of LDL-C lowering with evolocumab on MACE in adults at high CV risk without prior heart attack or stroke. Results were published in the New England Journal of Medicine in November 2025. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization (4-P MACE). Repatha also reduced the risk of heart attack by 36%.VESALIUS-CV enrolled more than 12,000 patients with known ASCVD or high-risk diabetes, who had no history of heart attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab testing. Participants were randomized to receive Repatha or placebo in addition to optimized lipid-lowering therapy and were followed for a median of approximately 4.6 years.Amgen's Commitment to Cardiovascular Innovation
Cardiovascular disease (CVD) remains a major global health threat, linked to multiple interrelated risk factors like high LDL-C, Lp(a), obesity, diabetes and hypertension.7,8 These risks often coexist and require a comprehensive approach to prevention and care. Amgen is taking bold action, building on decades of leadership in CVD through LDL-C management to advance additional innovative, investigational treatments in the pipeline targeting common drivers of CVD. By combining scientific innovation with strategic partnerships to drive earlier testing, better care and broader access, Amgen's efforts reflect a sustained commitment to advancing both the science and the system of CV care.About Repatha
Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.Repatha is one of the most extensively studied PCSK9 inhibitors, with clinical and real-world evidence across diverse populations and CV risk profiles.8 The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients.9 Repatha is the only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention. Repatha has been prescribed to over 8 million patients globally and is approved in 74 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union.9 Applications in other countries are pending.INDICATIONS
 Repatha® is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor indicated:To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:adults with hypercholesterolemia.adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).The safety and effectiveness of Repatha® have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hypercholesterolemia. For full prescribing information, visit www.Repatha.com. IMPORTANT SAFETY INFORMATION   Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.Adverse Reactions in Adults with Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo. Adverse Reactions in Pediatric Patients with HeFH: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.Adverse Reactions in Adults and Pediatric Patients with HoFH: In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.Please see full Prescribing Information. About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.CONTACT: Amgen, Thousand Oaks
Madison Howard, 773-636-4910 (media)
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors) REFERENCESMartin SS, Aday AW, Allen NB, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025151(8)le41–e660. https://doi.org/10.1161/CIR.0000000000001303Jurin I, et al. Outcomes of patients with normal LDL-cholesterol at admission for acute coronary syndromes: lower is not always better. J Cardiovasc Dev Dis. 2024;11(4):120. https://doi.org/10.3390/jcdd11040120Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2024;76(13):1507-1516.Kalra DK, Ray KK, Bajaj A, et al.  Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis. J Clin Lipidol. 2026.Shapiro MD. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving. Circulation. 2022;146(15):1120-1122. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771-e862.Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham Study. Circulation. 2022:145(17):1324-1338. https://doi.org/10.1161/CIRCULATIONAHA.121.057889Tsimikas S, Marcovina S. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week. JACC. 2022;80(9):934-946. https://doi.org/10.1016/j.jacc.2022.06.019 MAC: REF-99099Data on File. Amgen, 2025.





View original content to download multimedia:https://www.prnewswire.com/news-releases/repatha-cuts-risk-of-first-major-cardiovascular-events-by-31-in-high-risk-patients-without-known-significant-atherosclerosis-302727943.htmlSOURCE Amgen

Original: REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

AMGN, shorts in control

AMGN, buy the dip

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDENDMarch 4, 2026 4:01 PM
PR Newswire (US)

THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on May 15, 2026.About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads. Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors) 





View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-2026-second-quarter-dividend-302704267.htmlSOURCE Amgen

Original: AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

AMGN, new highs

AMGN, still trending higher

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMITFebruary 13, 2026 4:01 PM
PR Newswire (US)

THOUSAND OAKS, Calif., Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads. CONTACT: Amgen, Thousand Oaks?
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors) 





View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2026-virtual-oncology-leadership-summit-302687989.htmlSOURCE Amgen

Original: AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGN, there it goes

Amgen Tops Forecasts, Delivers Robust 2026 Outlook as Shares Edge HigherFebruary 4, 2026 6:19 AM
IH Market News
Amgen (NASDAQ:AMGN) reported stronger-than-expected fourth-quarter results, posting solid revenue growth and upbeat guidance for 2026, which helped lift its shares slightly in premarket trading on Wednesday.The biotech group said quarterly revenue rose 9% year over year to $9.9 billion, beating the market consensus of $9.46 billion. Adjusted earnings per share came in at $5.29, well ahead of analysts’ expectations of $4.73. Product sales increased 7%, supported by 10% volume growth, although this was partly offset by a 4% decline in net selling prices.“Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth,” CEO Robert Bradway said in a statement.For the full year, Amgen reported a 10% increase in total revenue to $36.8 billion compared with 2024. The company noted that 18 products achieved record annual sales, with 14 medicines each generating more than $1 billion in revenue over the year.Several products stood out in the fourth quarter. Repatha posted a 44% year-on-year sales increase to $870 million, while Evenity rose 39% to $599 million. Tezspire recorded a 60% surge in sales to $474 million, and Imdelltra contributed $234 million during the quarter.Looking ahead, Amgen issued its 2026 outlook, forecasting revenue in the range of $37.0 billion to $38.4 billion, compared with a consensus estimate of $37.1 billion. Adjusted earnings per share are expected to fall between $21.60 and $23.00, versus analysts’ expectations of $22.10.“2026 revenue guidance was slightly above consensus” despite the rollout of several biosimilars—lower-cost versions of biologic drugs—targeting Amgen’s Prolia osteoporosis treatment, analysts at Leerink Partners said in a note.Amgen generated $8.1 billion in free cash flow in 2025, down from $10.4 billion in the prior year, which the company attributed mainly to the timing of working capital movements and higher capital spending.Amgen stock price

Original: Amgen Tops Forecasts, Delivers Robust 2026 Outlook as Shares Edge Higher

AMGN, still above the 20 sma

AMGN, dollar cost average

Looks like a good swing

AMGN hanging in there

AMGN, still bouncing off the 50:sma

AMGN, bounced off the 50:sma

AMGN, took a hit after the recent 52 week high

🌱 Arthritis: Herbal Balm vs. Synthetic Anti-Inflammatories
Medical cannabis: Topical creams and infused balms are positioned as natural anti-inflammatory remedies, appealing to patients wary of long-term NSAID use.

Biotech/Pharma: Pharma companies rely on lab-made painkillers, steroids, and biologics to suppress inflammation.

The clash: Cannabis is marketed as “nature’s anti-inflammatory,” while pharma stresses clinical trials and patented molecules. $ABBV $MSOS $WEED $TOKE $MJ

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176550768 $AMGN

AMGN 10 Q due 5/1

AMGN, not so good

Should recover to close at about $265 today, and gap up a few bucks tomorrow.

IMHO

EXPECTING LOWER

AMGN still under $400

CANCER BREAKTHROUGH OF ALL THE CANCER NATIONS RNAZ
https://www.eurekalert.org/news-releases/1055915

AMGN under $400

AMGN new 52 week high

AMGN new 52/week high

AMGN short chart

AMGN new 52=week high

AMGN new 52 weekhigh

AMGN new 52 week high

AMGEN INC is having a great day!

The price per share $294.845 +$17.82 (+6.43%)
Volume 3,390,182

https://stockcharts.com/h-sc/ui?s=AMGN

Amgen's Olpasiran Reduced Cholesterol Levels In 95% Of Patients In Mid-Stage Study
By Benzinga — 10:01 AM ET 11/07/22

Amgen Inc (NASDAQ:AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic cardiovascular disease (ASCVD).
These data were presented during the Nov. 6 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions.
Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in lipoprotein levels compared to placebo at week 36.
Related: Amgen Reports Q3 Higher Profit, Despite Slight Fall In Topline Growth.
At these doses (75 mg or higher), more than 98% of patients achieved a lipoprotein level of 125 nmol/L or less at week 36.
Overall, the rates of adverse events were similar in the olpasiran and placebo arms. The most common treatment-related adverse events were injection site reactions, primarily pain.
At week 36, lipoprotein levels increased by a mean of 3.6% in the placebo arm, whereas there were substantial reductions of Lp(a) levels in all of the olpasiran arms.
Placebo-adjusted mean percent reductions were 70.5% for 10 mg every 12 weeks, 97.4% for 75 mg every 12 weeks, 101.1% for 225 mg every 12 weeks, and 100.5% for 225 mg every 24 weeks.
Price Action: AMGN shares are up 0.90% at $271.47 on the last check Monday.

WAS SUPPOSED TO BE BIG IN pm

I was reading on another board where someone stated a possibility of AMGN buying out RGBP... Are there any comments on that?

wee

More great news. Should be back to 250 in no time from these mid 230’s

FDA approves Lumakras—(f/k/a AMG-510)—for_second-line KRAS-mutated NSCLC:

https://finance.yahoo.com/news/fda-approves-lumakras-sotorasib-first-164700884.html Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

LUMAKRAS has received accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The next goal for AMGN is to obtain approval in the first-line setting.

LOL. That mod spot is available